Back to newsroom

A hub dedicated to medical innovation at the Clinique de Genolier

Tuesday 16 November 2021

© Genolier Innovation Hub

The Clinique de Genolier and the Swiss Medical Network Group have laid the first stone of a new hub dedicated to medical innovation. Estimated at CHF 100 million, the Genolier Innovation Hub is set to open its doors by the end of 2023.

The Genolier Innovation Hub, a new research and development center, has just started construction in Genolier (canton of Vaud).

The mission of this new hub dedicated to medical innovation is to facilitate the transfer of pre-clinical experimentation to practical application, in the form of clinical trials or training of medical or non-medical personnel, for instance.

The Genolier Innovation Hub will be home to international companies and researchers active in the medtech, pharma and biosciences fields. Companies such as Accuray and Raysearch, which specialize in radiotherapy, will set up research and training centers there. Collaborations are planned with numerous partners also based in the Health Valley, such as the Biopôle and the Haute Ecole La Source.

From research to clinical implementation under one roof

The new hub will accelerate patient access to the latest products, technologies and services. It will directly bridge research conducted within companies and laboratories with their practical application to patients through clinical trials and testing.

The building will include laboratories, functional operating rooms, medical imaging rooms and radiotherapy bunkers, as well as offices and spaces dedicated to formal and informal meetings. A 300-seat auditorium will be available for conferences and training sessions.

The total cost of the project is estimated at CHF 100 million, including CHF 65 million for construction. The structural work is expected to be completed in the first half of 2023, for an inauguration scheduled for the end of the year.

Partager sur Twitter Partager sur Facebook Partager sur Whatsapp Partager sur LinkedIn Partager par mail
Back to newsroom

This website uses cookies to improve user experience. More information